Fuyuan Pharmaceuticals: Lidocaine and Prilocaine Aerosol Approved for Clinical Trials.

Fuyuan Pharmaceuticals announced that its wholly-owned subsidiary Fuyuan Pharmaceuticals has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for Lidocaine and Prilocaine Spray. This drug is used to treat primary premature ejaculation in adult men, with local administration as the route of administration, and it is classified as a Category 3 chemical drug. Fuyuan Pharmaceuticals has invested approximately 9.5477 million yuan in research and development expenses for this drug. Currently, Lidocaine and Prilocaine Spray have been approved in countries such as Germany, France, Italy, Spain, Portugal, and the UK, but no manufacturer has been approved domestically yet. There are a total of 11 companies in China that have applied for clinical trials of this drug.